【Polaris Pharmaceuticals-KY】Suspension of Phase III Clinical Trial for ADI-PEG 20 in Leiomyosarcoma (LMS)
NQ Score
46/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Polaris Pharmaceuticals announced on May 25, 2026, that it is suspending its Phase III clinical trial of ADI-PEG 20 combined with Gemcitabine and Docetaxel for Leiomyosarcoma (LMS) following a recommendation from the DSMB.
AI Analysis
Frequently Asked Questions
- Q: Why was the clinical trial suspended?
- A: Based on the recommendation of the Data Safety Monitoring Board (DSMB).